MGMT and glioblastoma: Based on this, the MecMeth/NOA-24 trial now explores the toxicity of a combination of MFA and standard TMZ, establishes a tolerable dose of MFA in this combination therapy in patients with relapsed MGMT-methylated glioblastoma (phase I), and ultimately searches for first signs of efficacy of this combination (phase II).